BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Armagan B, Sari A, Erden A, Kilic L, Erdat EC, Kilickap S, Kiraz S, Bilgen SA, Karadag O, Akdogan A, Ertenli I, Kalyoncu U. Starting of biological disease modifying antirheumatic drugs may be postponed in rheumatoid arthritis patients with multimorbidity: Single center real life results. Medicine (Baltimore) 2018;97:e9930. [PMID: 29595700 DOI: 10.1097/MD.0000000000009930] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Naffaa ME, Hassan F, Golan-Cohen A, Merzon E, Green I, Saab A, Paz Z. Factors associated with drug survival on first biologic therapy in patients with rheumatoid arthritis: a population-based cohort study. Rheumatol Int 2021;41:1905-13. [PMID: 34529109 DOI: 10.1007/s00296-021-04989-y] [Reference Citation Analysis]
2 Quartuccio L, Zabotti A, Del Zotto S, Zanier L, De Vita S, Valent F. Risk of serious infection among patients receiving biologics for chronic inflammatory diseases: Usefulness of administrative data. J Adv Res 2019;15:87-93. [PMID: 30581616 DOI: 10.1016/j.jare.2018.09.003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
3 Shadick NA, Gerlanc NM, Frits ML, Stolshek BS, Brady BL, Iannaccone C, Collier D, Cui J, Mutebi A, Weinblatt ME. The longitudinal effect of biologic use on patient outcomes (disease activity, function, and disease severity) within a rheumatoid arthritis registry. Clin Rheumatol 2019;38:3081-92. [PMID: 31353421 DOI: 10.1007/s10067-019-04649-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Marin-Jimenez I, Bastida G, Forés A, Garcia-Planella E, Argüelles-Arias F, Sarasa P, Tagarro I, Fernández-Nistal A, Montoto C, Aguas M, Santos-Fernández J, Bosca-Watts MM, Ferreiro R, Merino O, Aldeguer X, Cortés X, Sicilia B, Mesonero F, Barreiro-de Acosta M. Impact of comorbidities on anti-TNFα response and relapse in patients with inflammatory bowel disease: the VERNE study. BMJ Open Gastroenterol 2020;7:e000351. [PMID: 32337054 DOI: 10.1136/bmjgast-2019-000351] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
5 Dierckx S, Sokolova T, Lauwerys BR, Avramovska A, de Bellefon LM, Toukap AN, Stoenoiu M, Houssiau FA, Durez P. Tapering of biological antirheumatic drugs in rheumatoid arthritis patients is achievable and cost-effective in daily clinical practice: data from the Brussels UCLouvain RA Cohort. Arthritis Res Ther 2020;22:96. [PMID: 32345367 DOI: 10.1186/s13075-020-02165-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Kerola AM, Rollefstad S, Kazemi A, Wibetoe G, Sexton J, Mars N, Kauppi M, Kvien TK, Haavardsholm EA, Semb AG. Psoriatic arthritis, axial spondyloarthritis and rheumatoid arthritis in Norway: nationwide prevalence and use of biologic agents. Scand J Rheumatol 2022;:1-9. [PMID: 35014920 DOI: 10.1080/03009742.2021.1997436] [Reference Citation Analysis]
7 Seyhoglu E, Uyaroğlu OA, Erden A, Kilic L, Karadag O, Akdogan A, Bilgen SA, Ertenli I, Kiraz S, Kalyoncu U. QuantiFERON®-TB Gold In-Tube test can be used for screening latent tuberculosis before biological treatment in a Bacille Calmette-Guérin (BCG)-vaccinated country: the HUR-BIO single-center real-life results. Clin Rheumatol 2021;40:2027-35. [PMID: 33057917 DOI: 10.1007/s10067-020-05443-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]